Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCA6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $51,245
Award facts
- Contract value 100% obligated
- $51,245.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $51,245.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 266 mg/20 ml vials. This delivery order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense. The award carries a firm fixed-price structure with no set-aside designation and is scheduled for completion by December 26, 2025. EXPAREL is a specialty surgical product used for local infiltration anesthesia, reflecting the breadth of DMS Pharmaceutical Group's product portfolio supplied to federal military healthcare facilities.
DMS Pharmaceutical Group has demonstrated substantial contracting capability through numerous recent delivery orders from the Defense Logistics Agency's Medical Supply Chain division, positioning the company as a critical supplier within the federal pharmaceutical supply chain. The company's single-award indefinite delivery contract under PPV-G GEN V, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare operations globally. This delivery order represents one of multiple awards issued to the contractor under the broader prime vendor program, demonstrating consistent performance in fulfilling specialized pharmaceutical requirements for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FSCA6?
SPE2DR26FSCA6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FSCA6 worth?
The government has obligated $51,245 on SPE2DR26FSCA6.
Is contract SPE2DR26FSCA6 an order under another contract?
Yes. SPE2DR26FSCA6 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCA6 competed?
The extent of competition for SPE2DR26FSCA6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award